The clinical setback represents a significant hurdle for AstraZeneca's ambitious goal of reaching $80 billion in revenue by 2030. Throughout 2025 and early 2026, the company’s leadership had characterized the trial as a foundational value driver. Ruud Dobber, Executive Vice-President of the BioPharmaceuticals Business Unit, previously touted the study as the largest of its kind, while Sharon Barr, Executive Vice President of Biopharmaceutical R&D, told investors in February 2026 that the company expected to demonstrate landmark results regarding the drug's additive benefits.
AstraZeneca Faces Investor Scrutiny Following Failed Phase III Trial
AstraZeneca shares plummeted 8.4% on July 9, 2026, after the company’s flagship CARDIO-TTransform trial for the drug Wainua failed to meet its primary endpoint in treating ATTR cardiomyopathy. The unexpected result has triggered a securities investigation into whether the firm adequately disclosed risks to shareholders during earlier development stages.
Following the disclosure that the study missed its primary endpoint, legal firm Levi & Korsinsky LLP has launched an investigation on behalf of shareholders who suffered financial losses. The inquiry focuses on whether prior public statements regarding the drug's potential were misleading. Investors who purchased securities during the period leading up to the trial outcome are being evaluated for potential claims, regardless of whether they still hold the stock or reside outside the United States.
Comments (0)
No comments yet. Be the first!